HEMOGENYX PHARMACEUTICALS PLC Logo

HEMOGENYX PHARMACEUTICALS PLC

Develops CAR-T therapies for blood cancers, autoimmune disorders, and viral infections.

HEMO | IL

Overview

Corporate Details

ISIN(s):
GB00BYX3WZ24
LEI:
2138008L93GYU5GN6179
Country:
United Kingdom
Address:
6TH FLOOR, 60 GRACECHURCH STREET, EC3V 0HR LONDON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Hemogenyx Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for life-threatening diseases. The company develops new medicines and treatments targeting blood diseases, autoimmune disorders, and viral infections. Its pipeline includes immunotherapy product candidates, such as CAR-T cell therapies, for the treatment of blood malignancies like acute myeloid leukemia (AML). Hemogenyx is dedicated to creating breakthrough treatments to address significant unmet medical needs, including improving the safety and efficacy of bone marrow transplantation.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for HEMOGENYX PHARMACEUTICALS PLC and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-17 08:00
Legal Proceedings Report
Third Patient Safety
English 16.5 KB
2025-09-11 08:00
Regulatory News Service
Invitation to Participate at DCNY Summit
English 11.6 KB
2025-09-08 08:00
Regulatory News Service
Manufacturing Partnership with Made Scientific
English 13.2 KB
2025-09-03 14:57
Share Issue/Capital Change
Exercise of Warrants and Issue of Equity
English 11.8 KB
2025-08-15 08:00
Regulatory News Service
Third Patient Treated with HG-CT-1 CAR-T Therapy
English 12.2 KB
2025-07-31 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 10.1 KB
2025-07-29 09:00
Share Issue/Capital Change
Placing to Raise £250,000 and Director’s Dealing
English 26.5 KB
2025-07-16 08:00
Regulatory News Service
Hemogenyx Awarded Grant
English 14.6 KB
2025-06-30 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 9.6 KB
2025-06-03 15:02
Director's Dealing
Placing to Raise £451,250 and Director’s Dealing
English 26.1 KB
2025-06-03 08:00
Legal Proceedings Report
Second Patient Passes Initial Safety Tests
English 14.9 KB
2025-05-31 12:30
Post-Annual General Meeting Information
Resolutions passed at Annual General Meeting of Hemogenyx Pharmaceuticals plc o…
English 33.9 KB
2025-05-29 15:06
Post-Annual General Meeting Information
Result of AGM
English 27.1 KB
2025-05-20 21:50
Annual Report (ESEF)
Annual Report & Financial Statements for the Year Ended 31 December 2024
English 673.1 KB
2025-05-20 21:50
Annual Report
Annual Report & Financial Statements for the Year Ended 31 December 2024
English 2.4 MB

Automate Your Workflow. Get a real-time feed of all HEMOGENYX PHARMACEUTICALS PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for HEMOGENYX PHARMACEUTICALS PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Lipum AB Logo
Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.
Sweden LIPUM
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland LONN
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland MAB
Magle Chemoswed Holding AB Logo
A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.
Sweden MAGLE
Develops at-home diagnostic tests for the early detection of life-threatening cancers.
Germany N/A
Marinomed Biotech AG Logo
Develops virus-blocking products & immunology therapies via proprietary technology platforms.
Austria MARI
Matricelf Ltd. Logo
Develops personalized 3D neural implants from patient cells to treat spinal cord injuries.
Israel MTLF
MediciNova,Inc. Logo
Developing small-molecule drugs for neurology, respiratory, and liver diseases.
Japan 4875

Talk to a Data Expert

Have a question? We'll get back to you promptly.